Reuters - Up to 69 percent of men who
receive hormone deprivation therapy for prostate cancer will
experience some degree of cognitive impairment, such as in the
ability to concentrate, a review of published data suggests.
receive hormone deprivation therapy for prostate cancer will
experience some degree of cognitive impairment, such as in the
ability to concentrate, a review of published data suggests.
